Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 20/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 19/20 | 1.00 |
| ▸ | AURKA | O14965 | 12/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 9/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410282 | 1.00 | PDPK1 (1.00) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1317861 | 0.92 | PDPK1 (0.86) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1320418 | 0.91 | PDPK1 (1.00) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1319624 | 0.91 | PDPK1 (0.98) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1318073 | 0.90 | PDPK1 (0.82) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1318075 | 0.90 | PDPK1 (0.82) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1318076 | 0.90 | PDPK1 (0.82) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1316758 | 0.89 | PDPK1 (0.81) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1316760 | 0.89 | PDPK1 (0.81) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1316761 | 0.89 | PDPK1 (0.81) | PDPK1AURKBAURKAROCK1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| WO-2025080080-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, CONTAINING PDK INHIBITOR AS ACTIVE INGREDIENT | 한양대학교 산학협력단 | 2025-04-17 | — | — | WO | claimed |
| US-20250011425-A1 | COMPOSITIONS AND METHODS FOR IMPROVED T CELLS | UNIV TEMPLE (US) | 2025-01-09 | — | — | US | claimed |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| US-12024715-B2 | Compositions and methods for improved T cells | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-07-02 | — | — | US | claimed |
| US-20220235330-A1 | METHODS FOR CREATING INTEGRATION-FREE, VIRUS-FREE, EXOGENOUS ONCOGENE-FREE IPS CELLS AND COMPOSITIONS FOR USE IN SUCH METHODS | Cellular Engineering Technologies, Inc. (US) | 2022-07-28 | — | — | US | claimed |
| US-20190316095-A1 | METHODS FOR CREATING INTEGRATION-FREE, VIRUS-FREE, EXOGENOUS ONCOGENE-FREE IPS CELLS AND COMPOSITIONS FOR USE IN SUCH METHODS | Cellular Engineering Technologies, Inc. (US) | 2019-10-17 | — | — | US | claimed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | claimed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | claimed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | claimed |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250368634-A1 | PHENYL AMIDE COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235872-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | PDPK1 12/4885AURKB 262/4885AURKA 298/4885 |
| US-20250368634-A1 | PHENYL AMIDE COMPOUNDS AND METHODS OF USE | AADAC, DBI, ASNS | PDPK1 1654/4885AURKB 826/4885AURKA 1036/4885 |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | PDPK1, PLK3, PLK2 | PDPK1 1/4885AURKB 306/4885AURKA 162/4885 |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | POU2F1, POU2F2, PARP2 | PDPK1 200/4885AURKB 107/4885AURKA 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.